{"entity":{"id":"nct06992258","kind":"trial","name":"A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer","aka":["FRUITION"],"tldr":"A phase 2 trial of Fruquintinib, Trifluridine/tipiracil in colorectal cancer, run by Criterium, Inc., now recruiting.","summary":"A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer is a phase 2 interventional study registered as NCT06992258 by Criterium, Inc., with 120 participants planned, started 2025-10-27 and due to reach its primary completion in 2027-12-31. Interventions recorded: Fruquintinib+ Lonsurf (trifluridine and tipiracil), Fruquintinib. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06992258","url":"https://clinicaltrials.gov/study/NCT06992258"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["antiangiogenic","cytotoxic-chemotherapy","kinase-inhibitors"],"targets":[],"drugs":["fruquintinib","trifluridine-tipiracil"],"companies":["criterium"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06992258","phase":"2","setting":"A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer","sponsor":"Criterium, Inc.","started":"2025-10-27","startedType":"actual","enrolled":120,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06992258/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/"},{"id":"trifluridine-tipiracil","kind":"drug","name":"Trifluridine/tipiracil","route":"/drugs/trifluridine-tipiracil/"}],"company":[{"id":"criterium","kind":"company","name":"Criterium","route":"/companies/criterium/"}]}}